Only 11% of Clinical Trial Sponsors Fully Deployed AI by Late 2024

Adoption lags despite industry enthusiasm

By late 2024, only 11% of clinical trial sponsors and contract research organizations had fully implemented artificial intelligence in their trial operations, according to the WCG CenterWatch 2025 AI Benchmarking Report released in November. The finding, drawn from survey responses collected in September and October 2025 from more than 400 sponsors, CROs, and sites, establishes the first structured baseline for measuring AI maturity across the clinical research industry.

Another 22% of sponsors and CROs reported partial AI integration, meaning two-thirds of organizations remained in experimental phases rather than executing AI strategies at scale. The data was first reported by Clinical Trial Vanguard.

Why it matters

Clinical research organizations have lacked a credible reference point to evaluate their own AI progress. A site director testing AI for patient recruitment screening has had no way to gauge whether that work is ahead of competitors or trailing industry norms. This benchmarking report provides the comparative data needed to calibrate strategy and investment, particularly as major CROs commit substantial capital—ICON announced a $300 million multi-year digital investment—widening the gap between organizations with coordinated AI approaches and those still exploring use cases.

Where AI shows near-term promise

Respondents identified protocol design, trial start-up, and data management as functional areas with the strongest potential for efficiency gains. These domains align with where operational friction is highest and where time savings compound across a study's lifecycle.

The concentration of interest in these areas reflects practical constraints rather than abstract enthusiasm. Protocol design and start-up activities involve repetitive tasks with structured inputs—conditions where current AI tools demonstrate measurable performance improvements.

The conversion question

The critical metric for the next survey cycle is whether the 22% partial-implementation cohort converts to full deployment by late 2026. If that segment fails to shrink meaningfully, it will signal that operational barriers—not strategic intent—constrain adoption. That distinction matters for where the industry directs its next investment round: building new AI capabilities versus addressing integration challenges, regulatory clarity, or workforce training gaps.

The report gives lagging organizations a documented target rather than an abstract aspiration. For technology vendors and consulting firms, it identifies where the market sits today and which functional areas warrant immediate product focus.

The data was originally reported by Clinical Trial Vanguard, drawing on the WCG CenterWatch 2025 AI Benchmarking Report.